Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
Dated clinical, regulatory and corporate events for Vincerx Pharma, Inc.
How VINC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-12-31 | VIP943 | Phase 1 data readout | Phase 1 |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VIP943 Small moleculeNCT06034275 | Acute Myeloid Leukemia | Phase 1 | RECRUITING | 36 | Dec 31, 2025 | ||||||
| VIP152 Small moleculeCompletedNCT02635672 | Neoplasms | Phase 1 | COMPLETED | 110 | Nov 11, 2024 | ||||||
| VIP236 Small moleculeCompletedNCT05712889 | Neoplasms | Phase 1 | COMPLETED | 29 | Oct 10, 2024 |
Readouts, endpoints and source filings for every VINC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| OQY-3258 | solid tumors | Phase 1a/1b | 2025-01-29 | intracranial ORR: 41% (n=17); PFS: 4.6 (2.0-9.8) months; historical PFS: 2.8 (1.5-3.9) monthsRead More | Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258Read More |
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Seelenberger Alexander A.Officer (See Remarks) | Buy | 10,500 30,280 held | $0.95 | 08/11/2023 |
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 0.4 % (-33.3 %) | 1.58 M | 2.21 M | -11.33% ( -281.91 K) |
Shares sold short, counted twice a month.
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
How VINC ranks across every disease it competes in